TSHA
Taysha Gene Therapies, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$4.13Close
$1.2BMarket cap
$3.51 – $6.9852-week range
Nov 3, 2026Next report
Highlights
Cautions
- Not in an uptrend 1 of 8 trend conditions
- Lagging the market RS 12 · weaker than 88% of stocks over 12 months
- Far from its high 41% below its 52-week high
- Distribution down-day volume 1.6× up-day volume over 50 sessions
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
41%
1wk
up 4.3%
price change
1mo
down 15.2%
price change
12-month return
down 16%
market up 11% ·
its own down 28%
F-score
—
— Not assessed
Altman Z
4.44
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.8×
price / book
Earnings yield
down 12.2%
EBIT / enterprise value
Cheaper than
18%
of the market · expensive
Revenue growth
up 17%
year on year
EPS growth
—
latest quarter
Sales growth
down 100%
latest quarter · +0 pts
ROE
down 68%
return on equity
Free cash margin
down 960%
-$93.8M FCF
D/E
0.20
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-46% then +17%)
Trade setup
ATR%
6.3%
$0.26 a day · 2×ATR $3.61
RS
12 / 99
vs the universe
Trend
1 / 8
trend template
Relative volume
0.4×
vs 50-day average
Up/down volume
0.63
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 1 of 8
- 150-day average above the 200-day: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 39.1% over the year, from 205m to 285m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 11, 2026
Results reaction
Aug 11, 2026+1% vs market2 sessions after results
Financials
- Net -1115%
- Free cash -960%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | $2.5M | $15.5M | $8.3M | $9.8M |
| Operating income | -$43.0M | -$173.3M | -$162.4M | -$72.4M | -$91.5M | -$110.5M |
| Net income | -$60.0M | -$174.5M | -$166.0M | -$111.6M | -$89.3M | -$109.0M |
| Net margin | — | — | -6635% | -722% | -1072% | -1115% |
| Earnings per share | — | -$4.64 | -$3.78 | -$0.96 | -$0.36 | -$0.34 |
| Free cash flow | -$30.8M | -$132.3M | -$109.0M | -$76.9M | -$81.6M | -$93.8M |
| Free cash margin | — | — | -4357% | -498% | -979% | -960% |
| Cash | $251.3M | $149.1M | $87.9M | $143.9M | $139.0M | $319.8M |
| Long-term debt | — | $37.2M | $38.0M | $40.5M | $43.9M | $50.1M |
| Shareholders' equity | $251.3M | $95.4M | $949,000 | $74.9M | $71.5M | $246.9M |
| Shares outstanding | 37.76m | 38.47m | 63.21m | 186.96m | 204.94m | 285.05m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Mar 19, 2026 | Annual ↗ | Dec 31, 2025 | 78d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 12, 2025 | Quarterly ↗ | Jun 30, 2025 | 43d |
| May 15, 2025 | Quarterly ↗ | Mar 31, 2025 | 45d |
| Feb 26, 2025 | Annual ↗ | Dec 31, 2024 | 57d |
| Nov 13, 2024 | Quarterly ↗ | Sep 30, 2024 | 44d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Mar 19, 2024 | Annual ↗ | Dec 31, 2023 | 79d |
| Nov 14, 2023 | Quarterly ↗ | Sep 30, 2023 | 45d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 11, 2026 | Results ↗ |
| Jun 25, 2026 | Material agreement · Other events ↗ |
| Jun 22, 2026 | Regulation FD · Other events ↗ |
| Jun 2, 2026 | Shareholder vote ↗ |
| May 6, 2026 | Results ↗ |
| Mar 19, 2026 | Results ↗ |
| Nov 4, 2025 | Material agreement · Results ↗ |
| Oct 16, 2025 | Other events ↗ |
| Oct 9, 2025 | Other events ↗ |
| Oct 2, 2025 | Other events ↗ |
| Aug 12, 2025 | Results ↗ |
| Jun 3, 2025 | Charter or bylaws · Shareholder vote ↗ |